TY - JOUR
T1 - Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers
T2 - Maximising bias-reduction
AU - Stjepanovic, Neda
AU - Villacampa, Guillermo
AU - Nead, Kevin T.
AU - Torres-Esquius, Sara
AU - Melis, Guadalupe G.
AU - Nathanson, Katherine L.
AU - Teule, Alexandre
AU - Brunet, Joan
AU - y Cajal, Teresa R.
AU - Llort, Gemma
AU - Dienstmann, Rodrigo
AU - Rue, Montserrat
AU - Domchek, Susan M.
AU - Balmaña, Judith
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/6
Y1 - 2020/6
N2 - Background: Whether risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 carriers reduces the breast cancer (BC) risk is conflicting, potentially due to methodological issues of prior analysis. We analysed the association between premenopausal RRSO and BC risk in BRCA1/2 carriers after adjusting for potential biases. Methods: We analysed data from 444 BRCA1 and 409 BRCA2 carriers under age 51 with no cancer prior to genetic testing or during first 6 months of surveillance (to avoid cancer-induced testing bias and prevalent-cancer bias). Observation started 6 months after genetic testing (to avoid event-free time bias), until BC diagnosis, risk-reducing mastectomy (RRM) or death. A multistate model with four states (non-RRSO, RRSO, RRM and BC) and five transitions was fitted to characterise outcomes and to calculate the BC risk reduction after premenopausal RRSO (before age 51). A systematic review was performed to assess the association between premenopausal RRSO and BC. Results: During a mean follow-up of 4.3 years, 96 women (11.3%) developed BC (54 BRCA1, 42 BRCA2). The risk of BC after premenopausal RRSO decreased significantly in BRCA1 carriers (hazard ratio (HR) = 0.45 [95% confidence interval (CI):0.22–0.92]), but was not conclusive in BRCA2 carriers (HR = 0.77 [95%CI:0.35–1.67]). The systematic review suggested that premenopausal RRSO is associated with a decrease of BC risk in both BRCA1 and BRCA2 carriers. Conclusions: Premenopausal RRSO was associated with BC risk reduction in BRCA1 carriers, which can help guide cancer risk-reducing strategies in this population. Longer follow-up and larger sample size may be needed to estimate the potential benefit in BRCA2 carriers.
AB - Background: Whether risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 carriers reduces the breast cancer (BC) risk is conflicting, potentially due to methodological issues of prior analysis. We analysed the association between premenopausal RRSO and BC risk in BRCA1/2 carriers after adjusting for potential biases. Methods: We analysed data from 444 BRCA1 and 409 BRCA2 carriers under age 51 with no cancer prior to genetic testing or during first 6 months of surveillance (to avoid cancer-induced testing bias and prevalent-cancer bias). Observation started 6 months after genetic testing (to avoid event-free time bias), until BC diagnosis, risk-reducing mastectomy (RRM) or death. A multistate model with four states (non-RRSO, RRSO, RRM and BC) and five transitions was fitted to characterise outcomes and to calculate the BC risk reduction after premenopausal RRSO (before age 51). A systematic review was performed to assess the association between premenopausal RRSO and BC. Results: During a mean follow-up of 4.3 years, 96 women (11.3%) developed BC (54 BRCA1, 42 BRCA2). The risk of BC after premenopausal RRSO decreased significantly in BRCA1 carriers (hazard ratio (HR) = 0.45 [95% confidence interval (CI):0.22–0.92]), but was not conclusive in BRCA2 carriers (HR = 0.77 [95%CI:0.35–1.67]). The systematic review suggested that premenopausal RRSO is associated with a decrease of BC risk in both BRCA1 and BRCA2 carriers. Conclusions: Premenopausal RRSO was associated with BC risk reduction in BRCA1 carriers, which can help guide cancer risk-reducing strategies in this population. Longer follow-up and larger sample size may be needed to estimate the potential benefit in BRCA2 carriers.
KW - BRCA1/2
KW - Breast cancer risk
KW - Multi-state model
KW - Risk reduction methodology
KW - Salpingo-oophorectomy
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=85083359042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083359042&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2020.03.009
DO - 10.1016/j.ejca.2020.03.009
M3 - Article
C2 - 32325420
AN - SCOPUS:85083359042
SN - 0959-8049
VL - 132
SP - 53
EP - 60
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -